A clinical extension study to evaluate the safety, tolerability and efficacy of AIN457 in multiple sclerosis patients with relapses
- Registry ID
- EUCTR2011-001629-25
- Source registry
- EUCTR
- Status
- Prematurely Ended
- Phase
- PHASE2
- Sponsor
- Novartis Pharma Services AG
- Start date
- 2012-01-10
- Completion date
- 2014-01-22
- Last update
- 2026-08-16
Conditions
- relapsing-remitting multiple sclerosis
Summary
To assess the long-term safety and tolerability of AIN457 over a period of up to 1 year in patients with relapsing-remitting multiple sclerosis who particpated in the core CAIN457B2201 Phase II proof of concept (PoC) study
Locations
View on source registry